IDYA
Ideaya Biosciences Inc
36.60$
-3.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
Ideaya Biosciences Inc (IDYA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -163 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.5 | -5.9 | -8.7 | -7.5 | -9.8 | -10 | -11 | -8.7 | -9.5 | -14 | 90 | -12 | -14 | -13 | -12 | -17 | -20 | -20 | -24 | -23 | -28 | -33 | -30 | -24 | -44 | -33 | -49 | -122 | -60 | -62 | 142 | -90 | -75 | -163 | -187 | |
| 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 1.1 | 0.8 | 0.4 | 0.8 | 0.9 | 0.9 | -0.5 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 1.0 | 0.6 | 1.1 | 1.2 | 1.0 | 1.2 | 1.1 | 2.3 | 5.6 | |
| 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.7 | 0.8 | 0.8 | 1.0 | 1.0 | 1.9 | 2.1 | 2.2 | 2.1 | 2.6 | 3.0 | 3.0 | 3.0 | 3.7 | 4.7 | 5.3 | 4.8 | 6.3 | 9.7 | 9.2 | 9.5 | 10 | 12 | 12 | 12 | 15 | 31 | 70 | |
| 0.0 | -0.1 | 4.0 | – | 0.1 | 0.4 | 0.5 | 0.7 | 0.8 | 0.8 | 1.1 | 1.4 | 1.9 | 2.5 | 2.2 | 2.1 | 2.6 | 3.0 | 3.0 | 3.0 | 3.7 | 2.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.9 | 0.1 | 0.6 | -0.7 | -0.3 | -0.4 | 1.0 | 1.4 | -2.6 | 94 | -8.3 | -7.5 | -5.6 | -4.3 | -1.4 | -9.4 | -2.0 | -2.9 | -0.5 | -7.3 | -8.7 | -5.5 | 8.3 | -5.3 | 16 | -2.3 | 3.4 | 4.2 | 4.6 | 12 | -19 | 8.9 | 16 | 18 | |
| 0.2 | 0.2 | 1.0 | 0.3 | 0.6 | 0.4 | 0.1 | 0.2 | 0.0 | 0.1 | 0.2 | 0.2 | 1.0 | 0.6 | 0.5 | 0.6 | 0.4 | 1.9 | 1.1 | 0.9 | 0.0 | 0.9 | 0.6 | 0.8 | 1.3 | 1.0 | 0.5 | 1.1 | 1.3 | 0.7 | 0.0 | 0.3 | 1.0 | 1.8 | 3.2 | |
| -60 | -15 | 5.3 | 6.6 | 25 | 11 | -38 | 3.9 | 11 | 31 | -184 | -4.6 | 36 | -49 | -56 | -0.4 | -18 | 13 | -19 | -10 | 24 | -121 | 51 | -112 | – | 69 | -20 | -197 | 80 | 46 | 42 | -98 | 119 | -37 | 26 | |
| 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | 58 | 0.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | 0.0 | 0.0 | 51 | -0.3 | 51 | 0.0 | – | 1.0 | 1.2 | 1.2 | 0.4 | 1.2 | -1.2 | 0.0 | -0.1 | 87 | 0.1 | 0.4 | – | – | – | – | – | 9.4 | – | – | – | – | – | 0.0 | – | – | |
| 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 105 | 0.0 | 0.0 | -0.1 | -0.8 | 52 | -0.3 | 0.0 | 0.0 | 95 | 27 | 6.9 | 42 | 16 | 87 | 0.7 | 0.7 | 0.5 | 96 | 0.3 | 2.9 | 191 | 28 | 141 | 349 | 39 | 287 | 2.8 | 26 | 1.2 | 0.3 | 2.1 | 1.2 | 360 | 364 | |
| 39 | -20 | -3.4 | -1.0 | 15 | 53 | -49 | -4.8 | 1.4 | 112 | -66 | -9.2 | 65 | -46 | 18 | -16 | -37 | -6.2 | 53 | -33 | -1.4 | 36 | 49 | 5.9 | -49 | 75 | 217 | -316 | 46 | -15 | 184 | -186 | 45 | 160 | 203 | |
| -5.7 | -6.1 | -9.7 | -7.8 | -10 | -11 | -11 | -8.9 | -9.5 | -14 | 90 | -12 | -15 | -14 | -13 | -17 | -20 | -22 | -25 | -23 | -28 | -34 | -31 | -25 | -45 | -34 | -50 | -123 | -62 | -63 | 142 | -91 | -76 | -165 | -190 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.